GLENMARK · NSE
Glenmark Pharmaceuticals Limited
₹2,447.4
+1.30% (+₹31.4)
Prev. close
₹2,416
Volume
5,45,520
Delivery %
66.5%
As of
18 Sept 2026
Price history
Jay Thakkar · ICICI Securities · 09 Sept 2026
“Bullish on Glenmark Pharmaceuticals futures, recommending a buy in the ₹2,480-2,490 range with a stop loss below ₹2,440 and targets of ₹2,560-2,600. The stock is in a clear uptrend, forming higher lows and highs, supported by long build-up and expected call unwinding from options data. ₹2,400 acts as strong support.”
Entry ₹2,480–₹2,490Target ₹2,560 (+3.2%)Stop ₹2,440 (-1.6%)R:R 2.0:1Never triggered — entry didn't fill
Published mid-session at 09:31 IST. Tracking counts only prices printed after publication — the chart's dashed divider marks that moment; earlier prices never count toward entry or results.
Analyst sentiment
Analysts lean bullish
5 analyst stances · last 90 days · one per analyst
Trackable
5 · 5 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Glenmark Pharmaceuticals futures, recommending a buy in the ₹2,480-2,490 range with a stop loss below ₹2,440 …” | Jay ThakkarICICI Securities | Glenmark Pharmaceuticals | PENDING | ||||
“Bullish on Glenmark Pharmaceuticals futures, recommending a buy in the ₹2,480-2,490 range with a stop loss below ₹2,440 and targets of ₹2,560-2,600. The stock is in a clear uptrend, forming higher lows and highs, supported by long build-up and expected call unwinding from options data. ₹2,400 acts as strong support.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
| “Bullish on Glenmark Pharmaceuticals, recommending a buy at CMP Rs 2,515 with a target of Rs 2,701 and a stop loss of Rs …” | Nilesh JainCentrum Finverse Ltd. | Glenmark Pharmaceuticals | PENDING | ||||
| “Bullish on Glenmark Pharma for intraday trading, recommending a buy at ₹2332 with a target of ₹2450 and a stop loss at ₹…” | Vaishali ParekhPrabhudas Lilladher | Glenmark Pharma | PENDING | ||||
| “The RSI Trending Up scan identified five Nifty500 stocks (MMTC, Glenmark Pharmaceuticals, Carborundum Universal, Muthoot…” | ETMarkets AnalysisETMarkets.com | Glenmark Pharmaceuticals Ltd | PENDING | ||||
| “Bullish on Glenmark Pharmaceuticals, recommending a buy with a target price of ₹2,470 and a stop loss of ₹2,260. The sto…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Glenmark Pharmaceuticals | PENDING | ||||
Fundamentals
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab and ISB 830-X8, a OX40 antagonist mAb for the treatment of atopic dermatitis. In addition, the company offers Ryaltris, fixed-dose nasal spray for the treatment of allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Glenn Mario Saldanha
Headquarters
Mumbai
Employees
16,946
Website
glenmarkpharma.comExchange
View on NSE ↗Key stats
Market cap
₹68,185.48 Cr
P/E ratio (TTM)
38.0
Dividend yield
0.31%
EPS (TTM)
₹63.62
Beta (1Y · daily vs NIFTY 50)
0.87
Beta (5Y · monthly vs NIFTY 50)
0.86
Shares float
14.16 Cr
EPS · quarter ended Jun 2026
₹17.11
Upcoming earnings
30 Oct 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹10,943.93 Cr | ₹12,304.90 Cr | ₹11,431.94 Cr | ₹11,813.10 Cr | ₹13,321.74 Cr | ₹16,982.51 Cr | |
| EBITDA | ₹2,179.14 Cr | ₹2,226.06 Cr | ₹1,200.15 Cr | ₹1,183.27 Cr | ₹2,092.28 Cr | ₹2,766.95 Cr |
| ₹970.09 Cr | ₹941.71 Cr | ₹297.25 Cr | ₹-1,501.67 Cr | ₹1,047.10 Cr | ₹1,361.85 Cr | |
| Diluted EPS | ₹34.38 | ₹33.37 | ₹10.53 | ₹-53.22 | ₹37.1 | ₹48.24 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹15,575.00 Cr | ₹17,052.00 Cr | ₹19,371.00 Cr | ₹14,358.00 Cr | ₹15,991.00 Cr | ₹19,907.00 Cr | |
| — | ₹3,962.02 Cr | ₹4,607.88 Cr | ₹1,230.93 Cr | ₹2,472.67 Cr | ₹593.53 Cr | |
| Stockholders' equity | ₹7,064.00 Cr | ₹9,086.00 Cr | ₹9,474.00 Cr | ₹7,848.00 Cr | ₹8,849.00 Cr | ₹10,512.00 Cr |
Current assets, Inventory, Cash & equivalents, Non-current assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,131.00 Cr | ₹1,109.00 Cr | ₹625.00 Cr | ₹-265.00 Cr | ₹-828.00 Cr | ₹3,445.00 Cr | |
| Investing cash flow | ₹-675.24 Cr | ₹-333.28 Cr | ₹-528.49 Cr | ₹4,560.89 Cr | ₹2.09 Cr | ₹-1,283.23 Cr |
| ₹-442.00 Cr | ₹-520.00 Cr | ₹-77.00 Cr | ₹-3,906.00 Cr | ₹787.00 Cr | ₹-2,709.00 Cr | |
| Capital expenditure | ₹-775.00 Cr | ₹-790.00 Cr | ₹-608.00 Cr | ₹-898.00 Cr | ₹-751.00 Cr | ₹-1,358.00 Cr |
| End cash position | ₹1,138.10 Cr | ₹1,410.53 Cr | ₹1,443.03 Cr | ₹1,658.27 Cr | ₹1,675.71 Cr | ₹1,174.71 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 20 | Sep 21–Dec 23(10Q) | Mar 24 | Jun 24–Jun 26(9Q) |
|---|---|---|---|---|
| Promoter | 46.63% | 46.65% | 46.64% | 46.65% |
| Public | 53.37% | 53.35% | 53.36% | 53.35% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Glenmark Pharmaceuticals Limited | ₹68,185.48 Cr | ₹2,447.4 | 38.0 | 6.49 | 13.0% | 0.06 | +27.1% | +16.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 27
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
41 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.